| Wang, Sanbin |
NCT04271644: BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 80 | RoW | BCMA CAR-T cells | Chongqing Precision Biotech Co., Ltd | Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse | 12/23 | 07/24 | | |
NCT04271410: CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma |
|
|
| Recruiting | 1/2 | 80 | RoW | CD19 CAR-T cells | Chongqing Precision Biotech Co., Ltd | Leukemia, Lymphoma, Large B-Cell, Diffuse, Leukemia, B-cell, Lymphoma, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell | 12/23 | 07/24 | | |
NCT04649983: CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma |
|
|
| Recruiting | 1/2 | 40 | RoW | CD19 and CD22 targeted CAR-T cells | Chongqing Precision Biotech Co., Ltd | Leukemia, B-cell, Lymphoma, B-Cell | 12/23 | 07/24 | | |
NCT04265963: CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1/2 | 45 | RoW | CD123 CAR-T cells | Chongqing Precision Biotech Co., Ltd | Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute | 12/23 | 07/24 | | |
NCT04781634: a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL |
|
|
| Recruiting | 1/2 | 40 | RoW | CD19 and CD22 targeted prime CAR-T cells | Chongqing Precision Biotech Co., Ltd | B-ALL | 12/23 | 07/24 | | |
NCT04776330: a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 80 | RoW | BCMA targeted prime CAR-T cells | Chongqing Precision Biotech Co., Ltd | Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse | 12/23 | 07/24 | | |
NCT04782193: a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma |
|
|
| Recruiting | 1/2 | 40 | RoW | CD19 and CD22 targeted prime CAR- T cells | Chongqing Precision Biotech Co., Ltd | B Cell Lymphoma | 12/23 | 07/24 | | |
NCT06210243: C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 1 | 24 | RoW | C752 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Shanghai PerHum Therapeutics Co., Ltd. | Lymphoma, B-Cell, CAR-T | 12/24 | 12/25 | | |
NCT05105867: CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies |
|
|
| Recruiting | 1 | 15 | RoW | Anti-CD19 Universal CAR-T Cells injection | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Gracell Biotechnology Shanghai Co., Ltd., Kunming Hope of Health Hospital | Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B-cell Non-hodgkin Lymphoma | 08/24 | 11/24 | | |
NCT06110208: Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML |
|
|
| Recruiting | 1 | 18 | RoW | CLL1 and CD38 dual-target CAR-T injection | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Gracell Biotechnology Shanghai Co., Ltd. | Acute Myeloid Leukemia | 08/26 | 10/26 | | |
NCT05015920: A Study Evaluating the Safety and Efficacy of the BD211 Drug Product in β-Thalassemia Major Participants |
|
|
| Recruiting | N/A | 10 | RoW | BD211 Drug Product | Shanghai BDgene Co., Ltd., 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Hematologic Diseases | 02/25 | 02/25 | | |
NCT06515262: Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM |
|
|
| Recruiting | N/A | 10 | RoW | Anti-BCMA-GPRC5D CAR-T cells infusion | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Guangzhou Bio-gene Technology Co., Ltd | Relapsed/Refractory Multiple Myeloma | 11/26 | 12/26 | | |
